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Abstract 
The venom of the scorpion, lltps serrulatus, was fractionated to investigate the chemical and pharmacological properties of its a-toxin content. 
Three a-toxins (Ts III, Ts IV and Ts V) were purified by conventional chromatography (gel filtration and ion-exchange chromatography), followed 
by immunoafhnity chromatography. Competition experiments using reference a- and/I-toxins suggested that these u-toxins were contaminated with 
around 0.01% of/I-toxin. The sequence of the first 30 amino acids of Ts IV was established. Using an oligonucleotide probe, a cDNA encoding its 
precursor was cloned from a venom gland cDNA library. The primary structure deduced from the cDNA nucleotide sequence provides possible 
explanations for the polymorphism of these three molecules. 
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1. Introduction 
The study of the venom from the Brazilian scorpion, 
Tiryus serrulutus, by numerous authors using different 
methods has led to the isolation of several toxins [l-5]. 
Two types of toxins (a- and p-toxin) have been charac- 
terized in this venom according to their specific binding 
to sites 3 and 4, respectively, on the voltage-gated sodium 
channel of rat brain synaptosomes [5,6] and their differ- 
ent electrophysiological activities (d-toxins inactivate the 
channel and #I-toxins act at the activation of the channel) 
[7,Q. 
The most potent B-toxin is Ts VII, also called Ts y 
[2,5-7,9,10]. We recently reported the cDNA nucleotide 
sequence ncoding the Ts VII precursor [ 111. 
The preparation containing one a-toxin, which was 
the first toxin purified from i? serrulutus venom (because 
of its high toxicity for mammals by subcutaneous injec- 
tion), was previously termed Tityustoxin [1,6,8]. The pri- 
mary structure of this molecule was not determined. The 
sequence of the first 55 amino acids of the a-toxinIV-5 
(which is probably the same molecule as Tityustoxin 
[1,2], has been published [3]. Recent work assumed that 
Tityustoxin was highly heterogeneous and that its vari- 
ous reported biological activities were due to the pres- 
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ence of several different components [4]. As Tityustoxin 
has often been used in biological and electrophysiologi- 
cal studies, it would be valuable to define its binding 
characteristics and to completely elucidate its primary 
structure. We therefore investigated the chemical and 
pharmacological properties of this toxin, using genetic 
and others approaches. 
2. Materials and methods 
ntyus serrulatus venom (1 g) was obtained from scorpions collected 
near Santa Barbara MG, Brazil. Sephadex G50 was from Pharmacia 
and the CM-cellulose CM,, from Whatman Inc. The toxicity of the 
chromatographic fractions was assayed either by subcutaneous ( .c.) or 
intracerebroventricular injection (i.c.v.) into C57 Bl/6 mice [12]. Poly- 
acrylamide gel electrophoresis was performed at pH 4 on a 20% homo- 
geneous Phast-gel using a Phastsystem according to the manufacturer’s 
instructions (Separation 6le 121, development tile 200). Amino acid 
analysis was performed using a Beckman 6300 analyzer, and automatic 
sequencing of the toxin was performed in a Beckman 890 C microse- 
quencer as described [12]. Reference a- and B-toxins (i.e. AaH II and 
Css II, respectively) and Ts VII were purified in the laboratory and 
radioiodinated according to published procedures [9,13]. Binding com- 
petition assays with ‘Z51-labeled a- or/I-toxin on rat brain synaptosomes 
were performed as previously described [13]. Polyclonal sera against Ts 
VII were obtained in New Zealand rabbits and were characterized as 
described [14]. Rabbit anti-Ts VII IgG was puritied on an AtIipak 
pre-packed column (Pierce Chemical Co.) and immobilized on CNBr- 
Sepharose for purification of Ts IV by aflinity chromatography. Radi- 
oimmunoassay (RIA) against [ltiI]Ts VII (2 x lo-“’ M) was performed 
with Ts IV submitted or otherwise to immunoafEnity chromatography 
using Ts VII antiserum (diluted l/100) as described [14]. 
Standard recombinant DNA techniques were used [15]. Enzymes 
were from Biolab. Escherichia coli strains C600 hfl and JM 109 were 
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used for phage production. The construction of the venom gland cDNA 
library has previousfy been described in detail [1 I]. The &tlO library 
contained 2.5 x lo6 independent phage clones. The oligonucleotide 
probe used to screen the library was synthesized using an Applied 
Biosystems Model 391 DNA synthesizer. The sequence of the degener- 
ate probe was 5’ TG(CT)TGG~(CT)TA(C~GA(~T)~(~~3’ 
and corresponded to the nucleotide sequence ncoding amino acids 
15-22, as determined by Rdman degradation. The probe was IzP-end 
labelled using T4 pol~ucl~tide kinase. 750,~ clones from the cDNA 
library were analyzed as previously described [ 11,151. The cDNA inserts 
were excised from positive phage DNA with EcoRI and were subcloned 
into Ml3 mp18 for sequencing [11,15]. 
3. Results 
The [r: serrulatus venom was dialysed against distilled 
water to eliminate salts and small peptides of 
MW < 3,500. Gel filtration through Sephadex G50 gave 
four toxic fractions (labelled Sl to S4 in Fig. 1A). Frac- 
tion S4, which was able to displace the radiolabelled 
a-toxin ([r2’I]AaH II) from its binding site on rat brain 
synaptosomes, was further separated on CM-cellulose 
CM52 into four toxic fractions (Fig. 1B): each of the 
fractions were homogeneous as assessed by POlY- 
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Fig. 1. Purification of Ts IV (A) Gel-filtration through Sephadex G50 
in 0. I M ammonium acetate buffer, pH 8.5; four columns (2.5 x 100 cm) 
in series; flow rate, 18 ml/h; Sl-S4, fractions toxic to mice by S.C. 
injection. (B) Chromatography on CM-cellulose CM52 of the fraction 
54 obtained in A, column 1 x 40 ml; elution buffers, equilibrium step 
(300 ml), 0.02 M a~onium acetate, pH 7, followed by an ~onium 
acetate gradient from 0.02 M, pH 7 (100 ml) to 0.15 M, pH 7 (100 ml); 
a second short equilibrium step (50 ml) of 0.15 M was followed by a 
gradient from 0.15 M, pH 7 (100 ml) to 2 M, pH 7 (100 ml); flow rate, 
20 ml/h. 
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A 
. ..‘<... TTG GTC GTC GTC TGC TTA TTG ACC GCG GGC ACG 
LVVVCLLTAGT 
GAG GGC AAG AAA GAC GGA TAC CCG GTG GAA TAC GAT AAC 
_&.__&KKDGYPVEYDN 
+l +lO 
TGC GCC TAC ATT TGC TGG AAC TAC GAC AAC GCT TAC TGC 
CAYICWNYDNAYC 
+20 
GAT AAG CTG TGC AAA GAC AX.2 AAA GCC GAT AGC GGA TAT 
D K L C K D K K A D S G Y 
c30 
TGT TAC TGG GTT CAC ATC CTG TGC TAC TGC TX GGG CTT 
CYWVHILCYCYGL 
+40 +50 
CCC GAT AGC GAA CCG ACC AAG ACC AAC GGA AAA TGC AAA 
PDSEPTKTNGKCK 
+60 
TCC GGT A.% hAG T&h ACCAGC~TCCTATTGATCCCAGATCCGCCCT 
s G K K * 
B 
l% III: ,.. G K C-OH 
+60 
TB IV: . . . G K C K s-N?iz 
+60 
TS v: . . . G K c K s G K-OH 
+60 +65 
Prw_xirsor: . . . G K C K S G K K-OH 
+60 c65 
Fig, 2. Nucleotide sequence of the cDNA encoding the Ts IV precursor. 
(A) The predicted protein sequence is given below the nucleotide se- 
quence and is numbered starting from the N-terminal amino acid resi- 
due of the toxin; the signal peptide sequence is underlined; the stop 
codon is designated by an asterisk; a potential polyadenylation signal 
is underlined twice. (B) Putative C-terminal sequences of Ts III, Ts IV 
and Ts V deduced from the possible different processing of the same 
precursor. 
acrylamide gel electrophoresis and staining for total pro- 
tein (data not shown). The toxins were numbered Ts III, 
Ts IV, Ts V and Ts VIII [5]. Their LD,, per 20 g mouse 
were: 2.5 pug, 0.4 ,ug, 0.2 pug and 7.2 pg, respectively, as 
determined by se. injection, and 20 ng, 24 ng, 15 ng and 
11 ng, respectively, by i.c.v. injection. The amino acid 
composition of Ts IV, the most active fraction by S.C. 
injection, was as follows: 11 Asp, 2 Thr, 3 Ser, 2 Glu, 3 
Pro, 4 Gly, 3 Ala, 8 Cys, 2 Val, 2 Ile, 3 Leu, 819 Tyr, 1 
His, 9 Lys, 2 Trp (spectrophotometrically determined). 
Met, Phe and Arg were absent. The amino acid compo- 
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sitions of Ts III and Ts V were quite similar: Ts III and 
Ts V only differed from Ts IV by 1 fewer Lys in Ts III 
and by an additional Lys and Gly in Ts V. Toxin Ts VIII 
has exactly the same amino acid composition as Ts VII, 
a B-toxin. 
The N-terminal amino acid sequence of Ts IV was 
established up to the 30th residue (except positions 12, 
16 and 24, which, by homology to other scorpion toxins, 
should be Cys) by automatic Edman degradation of 50 
nmol of native toxin and was found to be identical to 
toxin IV-5 [2,3]. 
The I: serrdatus cDNA library was probed with a 
32P-labelled oligonucleotide designed from amino acids 
16-22 of Ts IV, assuming that residue 16 was a Cys. 
Forty-two positive clones were selected and analyzed by 
restriction mapping. The twelve longest inserts (sized 
between 290 and 440 bp) were subjected to sequence 
analysis and found to encode the Ts IV precursor (Fig. 
2A). They differed from each other only by the length of 
the 5’ sequence and 3’ poly(A) tail. Even in the longest 
insert analyzed, no in-frame Met initiation codon was 
found, probably due to incomplete longation during the 
cDNA synthesis by reverse transcriptase. Thirty of the 
encoded amino acid residues match the N-te~inal se- 
quence of Ts IV and 55 that of toxin IV-5 [3]. Gly-Lys- 
Lys residues terminate the toxin precursor. Identically, 
the Ts VII precursor [l l] contains a Gly-Lys-Lys se- 
quence at the C-terminal, not present in the mature Ts 
VII. These three residues are presumably processed, the 
Lys residues being removed by a ~rbox~eptida~ and 
the remaining Gly-extended peptide being converted into 
a des-Gly peptide amine by an a-amidating enzyme to 
give an a-amidated C-terminal end. Previous reports de- 
scribe similar processing steps for the C-termini of other 
scorpion toxin precursors [12,16]. Thus, we suppose that 
the C-terminal residue (residue 64) of the mature Ts IV 
is a Seine-aide. From the precursor sequence of Ts IV 
deduced from the cDNA, it is also tempting to propose 
that Ts III and Ts V are immature forms of Ts IV 
digestion of the Ts IV C-terminal residues, i.e. Lys63 and 
Ser64, by exopeptidase would give Ts III; Ts V could 
exhibit an incompletely processed C-terminus and two 
additional residues: Gly65-Lys66 (Fig. 2B). 
In r~ptor-binding experiments (Fig. 3A and B), Ts 
III, Ts IV and Ts V all inhibited the binding of the 
a-toxin, [“‘I]AaH II (K,,, of lo-’ M, 3 x lo-’ M and lo-’ 
M, respectively) and the b-toxin [*2JI]Css II (KY,,, of 10v5 
M, lo-’ M and 3 x 10m5 M, respectively). Thus, each 
toxin seems to bind both sites 3 and 4 on the sodium 
channel. Ts IV also inhibited the binding (K,,s ratio = I/ 
lO,O~) of the /&toxin [i251]Ts VII to Ts VII antibodies 
when RIA were performed 1141, implying that Ts IV 
either shares common epitopes with Ts VII or that the 
Ts IV preparation contained residual contamination by 
Ts VII (0.01% w/w) or Ts VIII (1% w/w). To eliminate 
the second of these possibilities, the Ts IV preparation 
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was subjected to an additional immunoafhnity chroma- 
tography step on a column made with the IgG raised 
against the /&toxin Ts VII [14]. After filtration through 
this column, the Ts IV preparation was unable to dis- 
place [‘*‘I]Css II from its binding site but was still able 
to compete with [‘*?]AaH II with a K,,, of 3 x 10m7 M. 
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Fig. 3. Competition binding to rat brain synaptosomal fraction. (A) 
Competition experiments between the a-toxin, [‘*‘IjAaH II (o), and Ts 
III (A), Ts IV (m), Ts V (0) and Ts VIII (0). (B) Competition experi- 
ments between the&toxin, [‘zsI]Css II (*), and Ts VIII (cl), Ts IV before 
(m) and Ts IV after (A) ~unoaffinity c~omato~phy on an anti-Ts 
VII-IGg protein A-Sepharose column. Rat brain s~aptosom~ frac- 
tion (0.4 mglrnl) was incubated for 30 min at 37”C, with the a-toxin, 
[‘r?]AaH II (0.2 nM), or the B-toxin, [‘251]Css II (0.1 nM), and concen- 
trations of toxins. S, is the binding of either [‘r’I]AaH II and [‘2’I]Css 
II in the absence of toxins, and B is the binding in the presence of the 
indicated concentrations of toxins. Non-specific binding in the presence 
of an excess of unlabelied toxin (1 ,OOO-times xcess) has been sub- 
tracted. The incubation buffer used for competition with B-toxin 1141 
was: 2.5 mM HEPES, IO mM glucose, 154 mM choline, 5.4 mM potas- 
sium chioride, 0.1% bovine serum albumin, pH 7.2. 1.8 mM calcium 
chloride and 1 mM magnesium sulphate were added to the incubation 
medium for competition with a-toxin, as both cations are inhibitors of 
/&toxin fixation [ 141. Pellets were obtained by centrifugation (11,000 x g 
for 5 min), washed twice with cold buffer and the bound radioactivity 
counted in a y-spectrophotometer (Packard). 
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Its S.C. toxicity was unchanged. Ts VIII was defined with- 
out ambiguity as a p-toxin: it competed for site 4 of the 
Na’ channel with [‘2sI]Css II and not for site 3 with 
[‘2SI]AaH II. In spite of similar amino acid compositions, 
Ts VIII exhibited an affinity (K,,, of 5 x lo-” M) for its 
receptor loo-times lower than that of the potent B-toxin, 
Ts VII. 
4. Discussion 
On the basis of their amino acid compositions alone, 
it is quite difficult to identify with certainty the Tityus- 
toxin described by Diniz or toxin IV-5 described by Pos- 
sani et al. [1,2] as Ts III, Ts IV or Ts V (this study). 
However, Ts IV (the most abundant toxin and the most 
active by S.C. injection) could be Tityustoxin. The phar- 
macological characterisation of Ts IV shows that it is an 
a-type toxin. The presumed residual contamination of 
the p-type toxin, eliminated by immunoaffinity chroma- 
tography, was undetectable by conventional methods of 
protein chemical analysis because its concentration was 
low. However, this contamination was very significant 
for pharmacological characterization since the p-type ef- 
fect could be observed at concentrations of 100 nM. 
Probably, Ts III and Ts V are also a-toxins slighly con- 
taminated by p-type toxin(s). Ts VIII could be a denatu- 
rated form of Ts VII. Authors who have studied 7: ser- 
rulatus venom have demonstrated the complexity of the 
last fraction (S4) obtained by filtration and the polymor- 
phism of its components [1,2,4]. Possani et al. found that 
toxin IV-6 was identical to toxin IV-5 up to residue num- 
ber 30 and explained the difference in chromatographic 
behaviour by deamination of an Asn or a Gln of toxin 
IV-5 [2]. From this work, it can now be speculated 
whether different post-translational processing of the 
same precursor leads to the three mature peptides which 
vary only in their C-terminal sequence. The retention 
times observed for Ts III, Ts IV and Ts V on a cationic 
exchanger and their amino acid compositions differing 
by their Lys content are consistent with this scheme. 
MX Martin-Eauclaire et al. IFEBS Letters 342 (1994) 181-184 
These differences in amino acid sequence should be re- 
sponsible for the different a%nity and toxicity values 
determined in the biological experiments. 
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